Symptomatic patients with Huntington's disease may have reduced glucose metabolism in the caudate nuclei. We used positron emission tomography and [18F]fluorodeoxyglucose to study cerebral glucose metabolism in 95 subjects: 58 clinically asymptomatic (chorea-free) subjects at risk for Huntington's disease, 10 symptomatic patients with the disease, and 27 controls. All the symptomatic patients had marked reductions in caudate glucose metabolism. Despite a normal structural appearance on computed tomography, caudate glucose metabolism was bilaterally reduced in 31 percent of the subjects at risk (18 of 58). Using each at-risk subject's age and the sex of the affected parent, we averaged individual risk estimates for the development of Huntington's disease for this group and predicted that the probability of having the clinically unexpressed Huntington's disease gene should be 33.9 +/- 6.0 percent for the group. Thus, there was excellent agreement between the predicted percentage of carriers of the Huntington's disease gene (33.9 +/- 6.0 percent) and the percentage with metabolic abnormalities of the caudate nuclei (31 percent). These results indicate that the measurement of glucose metabolism may allow the observation of the pathophysiologic effects of the Huntington's disease gene during the natural development of the disease. It may also provide a direct means to monitor the response to experimental treatments during both the clinically asymptomatic and the symptomatic phases of the disorder.
This article has been cited by other articles:
Powers, W. J., Videen, T. O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J. V., Hershey, T., Perlmutter, J. S.
(2007). Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. USA
104: 2945-2949
[Abstract][Full Text]
Small, G. W.
(2006). Diagnostic Issues in Dementia: Neuroimaging as a Surrogate Marker of Disease. J Geriatr Psychiatry Neurol
19: 180-185
[Abstract]
Gonzalez-Alegre, P., Afifi, A. K.
(2006). Clinical Characteristics of Childhood-Onset (Juvenile) Huntington Disease: Report of 12 Patients and Review of the Literature. J Child Neurol
21: 223-229
[Abstract]
Teichmann, M., Dupoux, E., Kouider, S., Brugieres, P., Boisse, M.-F., Baudic, S., Cesaro, P., Peschanski, M., Bachoud-Levi, A.-C.
(2005). The role of the striatum in rule application: the model of Huntington's disease at early stage. Brain
128: 1155-1167
[Abstract][Full Text]
Thieben, M. J., Duggins, A. J., Good, C. D., Gomes, L., Mahant, N., Richards, F., McCusker, E., Frackowiak, R. S. J.
(2002). The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain
125: 1815-1828
[Abstract][Full Text]
de Almeida, L. P., Ross, C. A., Zala, D., Aebischer, P., Deglon, N.
(2002). Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length. J. Neurosci.
22: 3473-3483
[Abstract][Full Text]
Feigin, A., Leenders, K. L., Moeller, J. R., Missimer, J., Kuenig, G., Spetsieris, P., Antonini, A., Eidelberg, D.
(2001). Metabolic Network Abnormalities in Early Huntington's Disease: An [18F]FDG PET Study. JNM
42: 1591-1595
[Abstract][Full Text]
Paulsen, J. S., Zhao, H., Stout, J. C., Brinkman, R. R., Guttman, M., Ross, C. A., Como, P., Manning, C., Hayden, M. R., Shoulson, I.
(2001). Clinical markers of early disease in persons near onset of Huntington's disease. Neurology
57: 658-662
[Abstract][Full Text]
Pinborg, L H, Videbak, C, Hasselbalch, S G, Sorensen, S A, Wagner, A, Paulson, O B, Knudsen, G M
(2001). Benzodiazepine receptor quantification in Huntington's disease with [123I]iomazenil and SPECT. J. Neurol. Neurosurg. Psychiatry
70: 657-661
[Abstract][Full Text]
Reed, B. R., Eberling, J. L., Mungas, D., Weiner, M., Jagust, W. J.
(2001). Frontal Lobe Hypometabolism Predicts Cognitive Decline in Patients With Lacunar Infarcts. Arch Neurol
58: 493-497
[Abstract][Full Text]
Phelps, M. E.
(2000). Inaugural Article: Positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. USA
97: 9226-9233
[Abstract][Full Text]
Harris, G. J., Codori, A. M., Lewis, R. F., Schmidt, E., Bedi, A., Brandt, J.
(1999). Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain
122: 1667-1678
[Abstract][Full Text]
Hardy, J., Gwinn-Hardy, K.
(1998). Genetic Classification of Primary Neurodegenerative Disease. Science
282: 1075-1079
[Abstract][Full Text]
Soong, B.-w., Liu, R.-s.
(1998). Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J. Neurol. Neurosurg. Psychiatry
64: 499-504
[Abstract][Full Text]
Hahn-Barma, V, Deweer, B, Durr, A, Dode, C, Feingold, J, Pillon, B, Agid, Y, Brice, A, Dubois, B
(1998). Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry
64: 172-177
[Abstract][Full Text]
Bhide, P. G., Day, M., Sapp, E., Schwarz, C., Sheth, A., Kim, J., Young, A. B., Penney, J., Golden, J., Aronin, N., DiFiglia, M.
(1996). Expression of Normal and Mutant Huntingtin in the Developing Brain. J. Neurosci.
16: 5523-5535
[Abstract][Full Text]
Palfi, S., Ferrante, R. J., Brouillet, E., Beal, M. F., Dolan, R., Guyot, M. C., Peschanski, M., Hantraye, P.
(1996). Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington''s Disease. J. Neurosci.
16: 3019-3025
[Abstract][Full Text]
Marks, W. A., Shuman, R. M., Leech, R. W., Brumback, R. A.
(1988). Cerebral Degenerations Producing Dementia: Importance of Neuropathologic Confirmation of Clinical Diagnoses. J Geriatr Psychiatry Neurol
1: 187-198
[Abstract]
